Under the terms of the agreement, Axentis Pharma purchased from aRigen Pharmaceuticals an exclusive license for the development and commercialization of ARB-CF0223 worldwide except Japan and Korea. As part of the agreement, aRigen Pharmaceuticals received shares of Axentis Pharma plus an undisclosed sum in cash.
ARB-CF0223 is a fully patented, innovative encapsulating drug delivery system for the treatment of pulmonary infections in patients with cystic fibrosis. The system has an improved safety profile, higher efficacy and lower doses, and also reduces the frequency and severity of exacerbations compared to current treatments for pulmonary infections in patients with cystic fibrosis.
Jorg Zielasek, president of Axentis Pharma, saidthat: “The agreement means that Axentis can now initiate an immediate Phase II clinical trial in Germany. The design of the study has already been approved by the EMEA, which has also granted orphan drug status to ARB-CF0223.”